Theravance Inc. (THRX) announced after the bell Thursday that it received a letter from the FDA, which indicated that the company's response to the November 2009 Complete Response letter for the telavancin New Drug Application is incomplete and that the review clock will not start until the FDA receives a complete response.
Theravance Inc. gapped open sharply lower Friday and declined during the first 45 minutes of trade. Shares fell further going into the close and finished down by 2.53 at $10.97 on above average volume. The stock dropped below a 2-month range and set a new low for the year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.